Background: The FRAX ® is a validated tool that predicts ten-year probability of hip fracture and major osteoporotic fracture with or without the addition of femoral neck bone mineral density (BMD). The aim of this study was to use the FRAX ® score to determine if those presenting to our service with a hip fracture were on bone protection treatment pre hip fracture according to recommended guidelines. Methods: Demographics, DXA history, and osteoporosis medications were collected on hip fracture patients consecutively admitted to an orthogeriatric rehabilitation unit over a 3 month period (February to April 2017). The FRAX ® score was calculated (without the inclusion of BMD measurement) following the completion of a comprehensive questionnaire. Results: 36 patients were reviewed. 72% (26/36) were female. The average age was 81 years (range 66-97). 50% (18/36) had a previous fragility fracture. 17% (6/36) had a previous contralateral hip fracture, 2 had a prior vertebral fracture and the remainder were wrist, humeral and pelvic fractures. 17% (6/36) had a DXA. 39% (14/36) had been taking supplemental calcium and/or vitamin D. 33% (12/36) were on or had previously been on bone protection. Of the 24 patients not on treatment the range for pre-fracture FRAX score for 10 year probability of hip fracture was 4.1-50.1%. In line with the new UK NOGG guidelines 25% (6/24) should have been treated and 58% (14/24) should have had a DXA (BMD measurement). In the group of 8 patients who had a prior hip or vertebral fracture 38% (3/8) had not been treated. Conclusions: Our study highlights underutilisation of BMD measurement and bone protection medications in older patients with identifiable risk factors which may have reduced their hip fracture risk.
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